Company: OPGN
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001829126-25-008771
Chunk: 19

Company: OPGEN INC
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 guidance is effective for the Company’s fiscal year ending December 31, 2027 and can be adopted early. The Company
is in the process of evaluating the effects of this guidance on its condensed consolidated financial statements.

The Company has evaluated all other issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Note 4 – Revenue from contracts with customers

Disaggregated revenue

The Company provides listing sponsorship and consulting services to growth-stage private companies and, prior to its repositioning, the Company provided diagnostic test products and laboratory services to hospitals, clinical laboratories and other healthcare providing customers. The revenues by type of service consist of the following:

    Schedule of revenues by type of service

    Three Months Ended 
June 30,

    Six Months
    Ended June 30,

    2025

    2024

    2025

    2024

    Product sales
     
    $
    -

    $
    28,000

    $
    -

    $
    169,373

    Laboratory services

    -

    -

    -

    26,776

    Listing sponsorship services

    4,000,000

    -

    4,000,000

    -

    Total revenue
     
    $
    4,000,000

    $
    28,000

    $
    4,000,000

    $
    196,149

Revenues by geography are as follows:

    Schedule of revenues by geography

    Three Months Ended  June 30,

    Six Months
    Ended June 30,

    2025

    2024

    2025

    2024

    Domestic
     
    $
    -

    $
    28,000

    $
    -

    $
    196,149

    International

    4,000,000

    -

    4,000,000

    -

    Total revenue
     
    $
    4,000,000

    $
    28,000

    $
    4,000,000

    $
    196,149

    14

Deferred revenue

Changes in deferred revenue for the six months ended June 30, 2024
were as follows:

    Schedule of changes in deferred revenue

    Balance at December 31, 2023
     
    $